BridgeBio Pharma, Inc. (BBIO) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $27.20M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $15.97M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $192.19M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $27.20M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $27.20M |
| Deferred revenue · latest quarter (USD) | $15.97M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $5.55M + $10.42M ≈ $15.97M |
| Other obligations · due within 1 year (USD) | $192.19M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $192.19M |
| Other obligations · due after 1 year (USD) | $240.00K | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $240.00K − $0.00 ≈ $240.00K |
Calculation inputs
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $192.19M
- Other obligations · due after 1 year (USD)
- $240.00K
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $18.29M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $27.20M | $15.97M | $192.19M | $240.00K | $3.72B | (m) | $5.55M | $10.42M | $240.00K | $0.00 |
| 2026-03-31 | (m) | $29.06M | $17.89M | $135.51M | $229.00K | $3.64B | (m) | $6.12M | $11.78M | $229.00K | $0.00 |
| 2025-12-31 | (m) | $36.23M | $54.30M | $120.22M | $244.00K | $3.01B | (m) | $7.19M | $13.08M | $244.00K | $0.00 |
| 2025-09-30 | (m) | $18.70M | $22.22M | $92.74M | $679.00K | $2.92B | (m) | $9.09M | $13.13M | $679.00K | $0.00 |
| 2025-06-30 | (m) | $26.13M | $25.21M | $65.92M | $545.00K | $2.86B | (m) | $10.54M | $14.67M | $545.00K | $0.00 |
| 2025-03-31 | (m) | $27.52M | $29.13M | $40.67M | $352.00K | $2.52B | (m) | $11.62M | $17.51M | $352.00K | $0.00 |
| 2024-12-31 | (m) | $9.62M | $31.70M | (m) | $286.00K | $2.38B | (m) | $14.60M | $17.09M | $286.00K | $0.00 |
| 2024-09-30 | (m) | $13.36M | $30.40M | (m) | $377.00K | $1.88B | (m) | $11.77M | $18.63M | $377.00K | $0.00 |
| 2024-06-30 | (m) | $18.13M | $32.06M | (m) | $485.00K | $1.88B | (m) | $15.10M | $16.96M | $485.00K | $0.00 |
| 2024-03-31 | (m) | $4.73M | $33.85M | (m) | $595.00K | $1.89B | (m) | $13.96M | $19.89M | $595.00K | $0.00 |
| 2023-12-31 | (m) | $10.65M | (m) | (m) | (m) | $1.89B | (m) | $6.10M | (m) | $9.36M | (m) |
| 2023-09-30 | (m) | $4.47M | (m) | (m) | (m) | $1.85B | (m) | $6.59M | (m) | $11.79M | (m) |
| 2023-06-30 | (m) | $3.87M | (m) | (m) | (m) | $1.85B | (m) | $6.21M | (m) | $13.33M | (m) |
| 2023-03-31 | (m) | $4.08M | (m) | (m) | (m) | $1.84B | (m) | $6.67M | (m) | $17.50M | (m) |
| 2022-12-31 | (m) | $11.56M | (m) | (m) | (m) | $1.87B | (m) | $8.16M | (m) | $26.64M | (m) |
| 2022-09-30 | (m) | $10.16M | (m) | (m) | (m) | $1.86B | (m) | $7.52M | (m) | $28.23M | (m) |
| 2022-06-30 | (m) | $8.79M | (m) | (m) | (m) | $1.88B | (m) | $7.19M | (m) | $28.63M | (m) |
| 2022-03-31 | (m) | $10.11M | (m) | (m) | (m) | $1.85B | (m) | (m) | (m) | $26.83M | (m) |
| 2021-12-31 | (m) | $11.88M | (m) | (m) | (m) | $1.88B | (m) | (m) | (m) | $22.07M | (m) |
| 2021-09-30 | (m) | $12.04M | (m) | (m) | (m) | $1.52B | (m) | (m) | (m) | $27.58M | (m) |
| 2021-06-30 | (m) | $22.33M | (m) | (m) | (m) | $1.54B | (m) | (m) | (m) | $13.27M | (m) |
| 2021-03-31 | (m) | $10.34M | (m) | (m) | (m) | $1.48B | (m) | (m) | (m) | $11.61M | (m) |
| 2021-01-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $8.43M | (m) |
| 2020-12-31 | (m) | $8.95M | (m) | (m) | (m) | $595.70M | (m) | (m) | (m) | $9.52M | (m) |
| 2020-09-30 | (m) | $9.84M | (m) | (m) | (m) | $569.31M | (m) | (m) | (m) | $13.47M | (m) |
| 2020-06-30 | (m) | $12.84M | (m) | (m) | (m) | $577.72M | (m) | (m) | (m) | $9.40M | (m) |
| 2020-03-31 | (m) | $13.09M | (m) | (m) | (m) | $537.73M | (m) | (m) | (m) | $2.80M | (m) |
| 2019-12-31 | (m) | $8.85M | (m) | (m) | (m) | $155.70M | (m) | (m) | (m) | $3.53M | (m) |
| 2019-09-30 | (m) | $10.27M | (m) | (m) | (m) | $116.26M | (m) | (m) | (m) | $1.39M | (m) |
| 2018-12-31 | (m) | $13.51M | (m) | (m) | (m) | $87.58M | (m) | (m) | (m) | $495.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |